Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily fluticasone furoate/vilanterol vs fluticasone furoate in uncontrolled pediatric asthma
jRCT2080223880Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in asthma (3 arms), sponsored by GSK. Primary endpoints: Weighted mean FEV1 (0–4 hours) at Week 12 (5–17 years) and Change from baseline in pre-dose morning PEF averaged over Weeks 1–12 (5–11 years). Started Apr 2018; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223880.